Text Size
401 studies found for:    Open Studies | "Pancreatic Neoplasms"

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Not yet recruiting Gemcitabine and CT-011 for Resected Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of the Pancreas;   Neoplasms Pancreatic;   Pancreatic Cancer;   Pancreas Cancer
Interventions: Biological: CT-011;   Drug: Gemcitabine
2 Recruiting Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
Conditions: Cancer of Pancreas;   Cancer of the Pancreas;   Neoplasms, Pancreatic;   Pancreas Cancer;   Pancreas Neoplasms
Interventions: Drug: Modified FOLFIRINOX;   Radiation: Stereotactic Body Radiotherapy (SBRT)
3 Unknown † Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Conditions: Acinar Cell Carcinoma of Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Pancreatic Carcinoma Recurrent;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Pancreatic Carcinoma Stage III
Interventions: Drug: dasatinib;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Other: immunohistochemistry staining method
4 Unknown † Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
Conditions: Adenocarincoma of Pancreas;   Stage III Pancreatic Cancer;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer
Interventions: Drug: paclitaxel;   Drug: oxaliplatin;   Drug: leucovorin;   Drug: 5-fluorouracil;   Drug: glutathione;   Drug: calcium and magnesium;   Procedure: Chemotherapy;   Procedure: Chemoprotection;   Procedure: Complementary and alternative therapy
5 Recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: dinaciclib;   Drug: Akt inhibitor MK2206;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Recruiting Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Conditions: Pancreatic Neoplasms;   Pancreatic Cancer
Interventions: Drug: Gemcitabine and cisplatin;   Drug: Gemcitabine / Cisplatin
7 Recruiting Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Pancreatic Cancer
Intervention: Drug: Gemcitabine with escalating ascorbic acid
8 Recruiting Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: dasatinib;   Drug: erlotinib hydrochloride
9 Recruiting Combination Chemotherapy, Intensity-Modulated Radiation Therapy, and Surgery in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery
Conditions: Adenocarcinoma of the Pancreas;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Drug: capecitabine;   Radiation: intensity-modulated radiation therapy;   Drug: oxaliplatin;   Procedure: pancreatic surgical procedure;   Procedure: therapeutic conventional surgery
10 Recruiting Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas
Conditions: Pancreatic Cyst;   Pancreatic Neoplasms;   Pancreatic Adenoma;   Pancreatic Cancer;   Pancreatic Islet Cell Tumors;   Lymph Node;   Lymphadenopathy
Interventions: Procedure: EUS-FNA;   Device: nCLE
11 Not yet recruiting Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Conditions: Pancreatic Cyst;   Pancreatic Neoplasms;   Pancreatic Adenoma;   Pancreatic Cancer;   Pancreatic Islet Cell Tumors;   Lymph Node;   Lymphadenopathy;   GIST
Intervention: Device: EUS-FNA: Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle
12 Recruiting Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
Conditions: Metastatic Pancreatic Cancer;   Pancreatic Cancer
Intervention: Drug: Folfirinox
13 Not yet recruiting Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, and Urologic Cancers
Conditions: Healthy, no Evidence of Disease;   Localized Transitional Cell Cancer of the Renal Pelvis and Ureter;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Psychosocial Effects of Cancer and Its Treatment;   Recurrent Bladder Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Uterine Sarcoma;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage II Bladder Cancer;   Stage II Renal Cell Cancer;   Stage II Urethral Cancer;   Stage IIA Cervical Cancer;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Cervical Cancer;   Stage IIB Colon Cancer;   Stage IIB Gastric Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Colon Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Bladder Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage III Urethral Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Cervical Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IV Urethral Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Cervical Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Stage IVB Uterine Sarcoma;   Ureter Cancer
Interventions: Other: educational intervention;   Behavioral: telephone-based intervention;   Procedure: quality-of-life assessment;   Other: questionnaire administration
14 Recruiting Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer
Conditions: Localized Pancreas Cancer;   Non-metastatic Pancreas Cancer
Intervention: Other: FOLFIRINOX Regimen: Eloxatin (Oxaliplatin) Camptosar (Irinotecan Hydrochloride) Adrucil (Fluorouracil; 5-FU)
15 Recruiting Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Conditions: Colorectal Cancer;   Cancer of Pancreas;   Pancreatic Neoplasm;   Malignant Neoplasm of Large Intestine;   Malignant Tumor of Colon;   Colon Carcinoma;   Cancer of Colon;   Pancreatic Cancer
Interventions: Drug: FOLFOX6;   Biological: EGFRBi armed ATC Infusions
16 Recruiting Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
Conditions: Pancreatic Carcinoma Non-resectable;   Metastatic Pancreatic Cancer
Interventions: Drug: gemcitabine;   Drug: Erlotinib;   Radiation: low dose fractionated radiotherapy
17 Recruiting Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
Conditions: Pancreatic Cancer;   Unresectable Pancreatic Cancer
Intervention: Radiation: stereotactic body radiotherapy
18 Recruiting Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable;   Locally Advanced Malignant Neoplasm
Interventions: Drug: FOLFIRINOX;   Biological: HyperAcute®-Pancreas Immunotherapy;   Radiation: 5-FU Chemoradiation;   Drug: Gemcitabine
19 Recruiting Metformin Combined With Chemotherapy for Pancreatic Cancer
Conditions: Locally Advanced Pancreatic Cancer;   Metastatic Pancreatic Cancer
Interventions: Drug: gemcitabine;   Drug: erlotinib;   Drug: metformin;   Drug: placebo
20 Recruiting Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
Conditions: Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Stage III Colon Cancer;   Stage III Gastric Cancer;   Stage III Pancreatic Cancer;   Stage III Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer
Interventions: Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry;   Other: immunoenzyme technique;   Biological: modified vaccinia virus ankara vaccine expressing p53
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years